Q32 Bio Inc. (0T6G.L)
ValueMarkers Composite Index
39% below intrinsic value ($4)
Q32 Bio Inc. (0T6G.L) — VMCI valuation read
Composite valuation read on 0T6G.L: VMCI 62/100 against a Healthcare sector median of 50. The 12-point above-median print is the headline number for Q32 Bio Inc., and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.
Trailing 30-day insider activity for 0T6G.L: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.
**Investor frame.** Value, quality, risk in three lines on 0T6G.L: 0T6G.L trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 2.7x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.
0T6G.L fell 1.5% over the trailing 7 days, with a -12.7% read on a 30-day basis.
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.